Javtor/biomedical-topic-categorization-validation

PMID int64 35.7M 36.4M	Title/Abstract stringlengths 22 8.78k	MeshTerms stringlengths 7 101	SemanticTypes stringlengths 4 64
36,288,892	initi experi atezolizumab plus bevacizumab unresect hepatocellular carcinoma real world retrospect studi current studi evalu efficaci toxic atezolizumab plus bevacizumab patient advanc stage hepatocellular carcinoma real world set	D006528;D008113	T191
36,288,891	efficaci adjuv chemotherapi follow curat resect colorect cancer liver metastas routin use adjuv chemotherapi ac follow hepatectomi colorect liver metastas crlm univers practic lack support evid therefor investig efficaci ac follow curat crlm resect	D015179;D008113	T191
36,288,890	clinic impact primari cancer patient receiv curat treatment esophag cancer present studi evalu clinic impact metachron synchron primari cancer opc patient receiv curat treatment esophag cancer	D009378;D016609;D004938	T191
36,288,889	vascular non vascular fibula graft tumour reconstruct singl centr experi mid long term result vascular vfg non vascular fibula graft nvfg use reconstruct bone defect tumour resect studi compar autograft result risk factor complic	D019651;D001859	T061;T191
36,288,888	pan aurora kinas inhibitor danusertib induc apoptosi epstein barr virus transform b cell caspas endoplasm reticulum stress signal evid relev epstein barr virus ebv various type cancer expand howev definit mechan ebv induc oncogenesi remain ambigu purpos studi identifi relev aurora kinas ebv induc carcinogenesi cellular respons danusertib pan aurora kinas inhibitor under signal mechan ebv transform b cell also investig	D020031;D004854;D001402	T047;T005;T025
36,288,887	engulf cell motil elmo regul tumor cell behavior predict prognosi colorect cancer engulf cell motil elmo play crucial role process migrat chemotaxi metastasi tumor cell elmo implic pathogenesi various cancer howev distinct function elmo colorect cancer crc unclear determin whether elmo affect oncogen behavior crc cell investig prognost valu crc patient	D019938;D015179	T123;T191;T116
36,288,886	chang serum trace element concentr surgeri resect breast cancer miner trace element tes play vital role normal biolog function cancer breast carcinoma common occur cancer women aim studi evalu chang te level breast cancer surgeri clinic util reliabl te level assay use induct coupl plasma mass spectrometri icp ms	D002285;D001943;D018270;D014131;D012643	T121;T123;T196;T191
36,288,885	ptx treatment colon cancer mode action base tumor marker cytokin kinet cancer progress associ signific cachexia induc weight loss stomat pentoxifyllin ptx drug shown benefici anti inflammatori effect cancer patient main anti tnf mechan studi determin ptx effect mode action weight loss stomat surviv colon cancer patient treat chemotherapi examin kinet tumor marker cytokin level	D003110;D010431;D013280	T121;T047;T191;T109
36,288,884	signific chrp p delet cancer develop pan cancer silico analysi delet chrp locus relat develop sever type cancer main due presenc cdkna cdknb gene howev sever gene region potenti import tumorigenesi therefor aim analyz silico potenti prognost signific alter copi number express gene present chrp locus tcga dataset approxim patient	D000230;D010190;D002292;D005909;D005910;D007680	T191
36,288,883	interleukin il cytokin serum concentr correl pain score number analges dose follow surgeri anti proinflammatori cytokin plasma high sensit c reactiv protein hs crp use assess inflammatori stress respons isr follow surgeri howev serum il interleukin cytokin valu versus numer rate scale nrs pain score number analges dose nad postop unknown	D016207;D020382;D010149	T129;T047;T116;T184
36,288,882	contribut matrix metalloproteinas promot genotyp hepatocellular carcinoma suscept metalloproteinas mmp previous found regul hepatocellular carcinoma hcc specimen cell favor epitheli mesenchym transit howev contribut mmp genotyp hcc reveal date studi aim evalu contribut mmp promot g rs c rs genotyp risk hcc taiwan hcc incid extrem high compar worldwid data	D006528;D008113	T191
36,288,881	signific contribut interleukin genotyp childhood acut lymphocyt leukemia risk taiwanes evid shown interleukin il antitumor pro tumor effect various type leukemia current studi aim investig contribut il polymorph risk childhood acut lymphocyt leukemia taiwan	D020382;D054198	T129;T191;T116
36,288,880	molecular characterist immunogenom profil cholangioblast variant intrahepat cholangiocarcinoma year old patient cholangioblast variant intrahepat cholangiocarcinoma cvicc exceed rare primari biliari tract tumor typic occur young patient median age year old mimic metastat well differenti neuroendocrin tumor liver similar histolog immunophenotyp featur	D018281;D008113;D001650	T191
36,288,879	clinic impact nutrit inflamm assess tool gastric cancer treatment standard treatment gastric cancer surgic resect periop adjuv treatment multidisciplinari treatment gastric cancer lead nutrit inflammatori chang nutrit inflammatori chang multidisciplinari treatment lead poor physic activ sever toxic patient receiv chemotherapi radiat therapi poor oncolog outcom evalu periop nutrit inflammatori status treatment necessari order util optim multidisciplinari therapi gastric cancer physician abl detect periop nutrit inflammatori status gastric cancer treatment would abl select optim treatment periop nutrit treatment recent various type nutrit inflamm assess tool develop report gastric cancer nutrit inflamm assess tool clinic advantag eas implement periop access low cost hand tool clinic characterist must understood use clinic practic review summar background current status futur perspect applic nutrit inflamm assess tool gastric cancer treatment	D013274	T191
36,288,878	high express cd aldha predict poor prognosi basal like breast cancer cd immun adhes molecul cellular surfac previous found high express cd predict poor prognosi patient lower grade glioma therefor aim paper investig associ cd breast cancer	D001943	T191
36,288,877	candid oncogen arhgap nos orb develop scirrhous type gastric cancer scirrhous type gastric cancer sgc one intract cancer subtyp character rapid cancer cell prolifer infiltr accompani extens stromal fibrosi one reason poor prognosi may lack molecular target drug sgc unknown driver gene explor somat mutat human sampl sgc use next generat sequenc ngs hamper abund fibrous tissu sampl therefor studi aim determin novel oncogen rna sequenc use sgc cell line avoid contamin fibrosi	D002293;D013274	T191
36,288,876	establish characteris human clear cell sarcoma malign melanoma cell line clear cell sarcoma soft tissu ccsst convent malign melanoma mm rare aggress tumour similar morpholog express melanocyt marker	D018227;D008545	T191
36,288,875	oral recombin methioninas combin rapamycin erad osteosarcoma breast patient deriv orthotop xenograft mous model primari osteosarcoma breast rare malign share histolog featur osteosarcoma also high sensit methionin restrict due methionin addict previous establish patient deriv orthotop xenograft pdox nude mous model deriv tumor tissu patient primari mammari osteosarcoma present studi investig efficaci oral recombin methioninas rmetas combin rapamycin inhibitor mammalian target rapamycin mtor kinas mammari osteosarcoma pdox nude mous model	D001859;D012516	T191
36,288,874	determin clonogen radiosensit hela cell earli late g phase use fluoresc ubiquitin base cell cycl indic fucci recent report post irradi hela cell micronuclei frequenc increas earli g phase comparison late g phase inconsist result well recogn studi use clonogen assay studi determin radiosensit cell use clonogen assay make best use fucci properti simultan character cell cycl kinet dna damag respons	D011836	T032
36,288,873	surgeri limb edema health relat qualiti life prospect follow studi patient cutan malign melanoma latest develop oncolog therapi malign melanoma discoveri complet lymph node dissect offer surviv benefit chang landscap melanoma surgeri need inform health relat qualiti life hrqol consequ melanoma surgeri	D011788;D008545	T078;T191
36,288,872	evalu neoadjuv chemotherapi lower esophag squamous cell carcinoma measur esophag wall thick aim studi evalu efficaci preoper chemotherapi stage ii iii esophag squamous cell carcinoma base object comput tomographi method	D000077277;D004938	T191
36,288,871	pre postop circul tumour dna patient gastrointestin stromal tumour methodolog assess studi gastrointestin stromal tumour gist harbour genet aberr receptor tyrosin kinas kit kit platelet deriv growth factor receptor pdgfra patient circul tumour dna ctdna potenti biomark patient gist previous studi investig ctdna around surgeri patient gist present diverg result regard proport patient detect ctdna studi aim investig feasibl detect monitor ctdna pre postop compar two differ circul free dna cfdna extract method valid result obtain next generat sequenc ngs use real time pcr technolog	D046152;D000074141;D000073888	T123;T191;T114
36,288,870	impact knowledg base plan model improv plan complex deliver vmat prostat cancer multi institut studi studi evalu impact knowledg base plan kbp model improv plan complex deliveri accuraci volumetr modul arc therapi vmat prostat cancer multipl institut	D050397;D011471	T061;T191
36,288,869	develop novel small antitumor compound inhibit pd pd l bind anti program death pd pd ligand pd l antibodi success treatment patient solid cancer howev sever disadvantag need resolv oral small molecul anti pd pd l inhibitor develop good bioavail	D060890;D009369	T129;T191;T116
36,288,868	gustav roussi immun score predict postop complic non cancer death elder patient colon cancer gustav roussi immun grim score aa prognost marker various cancer type aim studi investig relationship grim score short long term outcom elder patient colon cancer	D009364;D003110	T191
36,288,867	effect cyclooxygenas canin melanoma deriv extracellular vesicl tumor microenviron vitro tumor cell deriv extracellular vesicl tev promot tumor growth metastasi thus drawn attent research tev regul tumor microenviron facilit crosstalk immun stromal cell macrophag one key compon involv malign behavior melanoma general activ macrophag polar pro inflammatori anti inflammatori pro tumor phenotyp howev role canin melanoma deriv ev macrophag polar elus studi aim analyz pro anti inflammatori cytokin common marker macrophag vitro	D000067128;D008545	T026;T191
36,288,866	associ high gene express variant chymas increas risk basal cell carcinoma previous studi associ certain variat gene encod factor renin angiotensin system ras indirect lead higher angiotensin ii angii level greater risk basal cell carcinoma bcc develop chymas cma main regul ras independ angii generat pathway numer studi shown oncogen potenti sever cancer type includ bcc studi investig possibl associ bcc pathogenesi function dna polymorph ag rs affect express cma gene	D002280;D012878	T191
36,288,865	thyroglobulin level predictor papillari cancer recurr thyroid lobectomi effect use serum thyroglobulin tg predict thyroid cancer recurr thyroid lobectomi unknown studi aim evalu predict natur serum tg tg trend thyroid lobectomi	D013954;D013964	T125;T121;T191;T116
36,288,864	clinicopatholog character primari diffus larg b cell lymphoma central nervous system primari central nervous system diffus larg b cell lymphoma cns dlbcl rare entiti account intracrani neoplasm studi aim investig clinicopatholog characterist primari cns dlbcl patient prognost implic	D016403;D016543	T191
36,288,863	surviv score elder patient brain metastas assign stereotact radiosurgeri fraction stereotact radiotherapi elder patient may benefit individu treatment surviv score creat patient age receiv radiosurgeri fraction stereotact radiotherapi brain metastas	D016634;D001932	T061;T191
36,288,862	neoadjuv therapi patient non small cell lung cancer complic chest wall invas multidisciplinari treatment includ anatom pulmonari chest wall resect recommend lung cancer complic chest wall invas present studi aim investig surviv benefit safeti preoper therapi follow surgeri non small cell lung cancer chest wall invas	D002289;D035441;D008175	T023;T191
36,288,861	letermovir prophylaxi cmv reactiv allogen stem cell recipi retrospect singl center analysi cytomegalovirus cmv reactiv one clinic signific complic allogen stem cell recipi frequent caus transplant relat mortal letermovir newli avail recent approv drug cmv prophylaxi retrospect singl center analysi investig benefit letermovir cmv prophylaxi allogen stem cell recipi	D003586;D018380	T061;T047
36,288,860	prognost signific nodal ratio number posit node patient squamous cell carcinoma head neck lymph node status high prognost relev head neck squamous cell carcinoma hnscc studi aim address hypothesi number posit node nodal ratio prognost impact surviv hnscc	D006258;D002294	T191
36,288,859	inhibit stat promot effector cell infiltr also immunosuppress hcc tumor microenviron stat involv progress sever cancer propos target therapi inde multitarget tyrosin kinas inhibitor drug regorafenib indirect inhibit stat signific enhanc effect anti program death receptor pd therapi hepatocellular carcinoma hcc model studi impact direct stat inhibitor tumor microenviron pd blockad efficaci hcc model	D006528;D008113;D013601	T191;T025
36,288,858	effect palliat care decis use hospit servic pancreat cancer patient retrospect studi continu chemotherapi use hospit servic near end life eol delay approach palliat care pc servic factor impair qualiti life near eol	D009369;D013727;D010190	T058;T191
36,288,857	prognost role porphyromona gingivali gingipain rgp matrix metalloproteinas oropharyng squamous cell carcinoma oral bacteria involv develop periodont alter tissu condit modifi immun respons way may also influenc tumor develop investig preval r gingipain rgp key virul factor oral pathobiont porphyromona gingivali tissu destruct enzym matrix metalloproteinas mmp mmp unselect consecut oropharyng squamous cell carcinoma opscc sampl investig relationship factor human papillomavirus hpv status treponema denticola chymotrypsin like proteinas td ctlp immunoexpress clinic paramet patient outcom	D030361;D009959;D006258	T047;T191
36,288,856	manag resist post transplant lymphoprolif disord car new option review therapeut option resistantrefractori post transplant lymphoprolif disord ptld relat chimer antigen receptor cell car therapi number possibl futur strategi treatment ptld follow method implement real world practic anti pd therapi checkpoint inhibitor nivolumab new anti cd ofatumumab brentuximab vedotin zanubrutinib howev innov method individu case success treatment rituximab resist epstein barr virus ebv ptld patient report far car innov method treatment base genet modif receptor autolog lymphocyt creat live drug therapi potent resist ptld lymphoprolifer b lymphocyt publish real world data patient treat car ptld indic success rate develop innov method treatment resistantrefractori ptld high rate resolut car therapi	D020031;D000076962;D008232	T129;T116;T192;T191;T047
36,288,855	hispan vs caucasian raceethn adrenocort carcinoma patient primari adrenocort carcinoma acc hispan raceethn may predispos higher stage initi diagnosi may result wors surviv test associ hispan raceethn cancer specif mortal csm acc patient addit test differ caus mortal ocm rate hispan caucasian	D018268;D000310;D000306	T191
36,288,854	suppress g protein coupl estrogen receptor gper enhanc anti invas efficaci select er agonist g protein coupl estrogen receptor gper often express tripl negat breast cancer tnbc gper respons mani non genom membran initi effect estrogen therefor analyz effect gper knockdown use specif sirna	D006528;D008113;D064726	T191
36,288,853	distress score cours radiotherapi pilot studi mani cancer patient receiv radiotherapi may caus distress pilot studi evalu distress level radiotherapi contribut design prospect trial	D009369;D000079225	T191;T048
36,288,852	potenti util mallampati score predict treatment complianc safeti profil patient head neck cancer undergo definit concurr chemoradiotherapi restrict mouth open rmo common manifest head neck cancer hnc poor prognost factor follow concurr chemoradiotherapi ccrt patient studi aim explor whether mallampati score visual assess distanc tongu base roof mouth use surrog rmo predict treatment outcom patient hnc undergo ccrt	D010984;D006258	T196;T191
36,288,851	prostaglandin dehydrogenas inhibit enhanc colon cancer metastasi regul epitheli mesenchym transit gene death colon cancer due metastasi recent pge found influenc colon cancer invas metastasi pgdh enzym metabol pge known tumor suppressor colon carcinogenesi studi investig effect pgdh colon cancer metastasi	D003110;D008113	T191
36,288,850	rechalleng lenvatinib atezolizumab plus bevacizumab treatment hepatocellular carcinoma atezolizumab plus bevacizumab lenvatinib key drug current system chemotherapeut regimen hepatocellular carcinoma hcc studi report potenti effect lenvatinib introduct atezolizumab plus bevacizumab treatment howev therapeut effect lenvatinib rechalleng atezolizumab plus bevacizumab treatment remain unclear	D006528;D008113	T191
36,288,849	luminophor chemistri detect urinari bladder cancer comparison cytolog urinari rapid test bta stat nmp bladderchek ubc rapid test new luminometr chelat develop detect urinari bladder cancer compar cytolog urinari rapid test bta stat nmp bladderchek ubc rapid test	D002295;D001749	T191
36,288,848	signific stage laparoscopi detect radiolog occult periton carcinomatosi gastric cancer gastric outlet obstruct consider optim treatment approach gastric cancer gastric outlet obstruct goo general found advanc stage unfavor prognosi studi perform examin preval radiolog occult periton carcinomatosi goo determin optim treatment strategi	D013274;D010534;D017219;D010535	T060;T047;T191;T061
36,288,847	detect recurr primari treatment oropharyng carcinoma post treatment surveil patient squamous cell oropharyng carcinoma scopc consist routin follow visit year suggest program ineffici find recurr increas surviv primari studi object investig recurr treatment scopc detect ie routin follow visit patient initi visit incident secondari object investig whether year surviv diagnosi recurr depend manner detect	D009959;D002294	T191
36,288,846	intravascular administr acridin orang zoledron bone metastasi model breast cancer studi evalu effect haematogen administr acridin orang ao alon combin zoledron zol bone metastas	D050071;D001859;D010014;D001943	T121;T191;T046
36,288,845	vater papilla preserv strategi advanc hepatocellular carcinoma excess bile duct tumor thrombus hepatocellular carcinoma hcc bile duct tumor thrombus bdtt high malign therefor continu multidisciplinari treatment essenti	D006528;D008113;D016461;D001650;D013927	T061;T191;T046
36,288,844	depress older adult covid pandem systemat review protocol depress common mental disord major caus year live disabl covid pandem caus increas preval depress worldwid aim identifi synthesis determin depress diagnost assess tool use evalu depress intervent carri sinc begin covid pandem popul age older	D000086382;D001523	T047;T067;T048
36,288,843	effect dri needl intervent lower limb dysfunct stroke studi protocol randomis control trial lower limb dysfunct among common sequela patient poststrok often result reduct qualiti life studi aim assess short interim term efficaci dri needl dn intervent lower extrem function balanc gait lower limb dysfunct stroke	D000071939;D000079245;D020521	T061;T047
36,288,842	prospect multicentr italian pregnanc cohort studi simpl associ matern first trimest simpl nutrit score earli placent function marker pregnanc outcom current adher nutrit guidelin low alarm rate obes worldwid micronutri defici document even industrialis countri consequ nutrit screen counsel repres critic subject earli pregnanc aim improv pregnanc outcom popul health	D011266;D018997	T125;T126;T116
36,288,841	fetal neonat matern pregnanc outcom women rheumatoid arthriti popul base cohort studi rheumatoid arthriti ra may advers influenc pregnanc lead advers birth outcom studi estim risk advers fetal neonat matern pregnanc outcom women ra	D001172;D011256	T033;T047
36,288,840	adapt popul health intervent new context qualit interview understand experi practic challeng research funder journal editor research adapt popul health intervent implement new context rapid expand accompani recent increas number framework guidanc support adapt process nevertheless remain limit explor real world experi undertak intervent adapt notabl challeng encount differ group stakehold manag understand experi imper ensur guidanc support adapt practic util qualit studi examin research stakehold experi fund conduct report adapt research	D000075485	T058
36,288,839	vulner popul malaria indoor residu spray withdrawn area use previous sustain protocol systemat review proven effect indoor residu spray ir malaria vector control strategi form one reliabl vector control strategi especi least popul cover howev date uncertainti regard consequ ir withdraw malaria control clear exit strategi place therefor need comprehens updat literatur regard malaria burden indic ir withdrawn follow sustain use	D008288;D000852	T047;T204
36,288,838	cohort profil swedish matern microbiom project swemami assess dynam associ microbiom matern neonat advers event swedish matern microbiom swemami project initi better understand dynam microbiom pregnanc longitudin microbiom sampl shotgun metagenom extens questionnair health registri linkag	D047928;D064307	T001;T032;T046;T028
36,288,837	cross section survey mental health addict effect servic impact care need children youth famili covid pandem covid masc studi protocol covid pandem tremend negat effect mental health well canadian mental health challeng especi acut among vulner canadian popul peopl live canada popul provinc ontario spent prolong time lockdown public health measur gap understand impact mental health system protocol describ mental health addict servic care studi use repeat cross section design examin effect impact need ontario adult covid pandem	D058873;D000086382	T047;T067
36,288,836	accept feasibl onlin inform linker servic caregiv child genet epilepsi mix method pilot studi protocol development epilept encephalopathi dee rare epilepsi condit collect impact children high genet heterogen result signific barrier accur adequ inform caregiv lead increas distress dissatisfact healthcar system address gap develop gene compass provid caregiv highest qualiti possibl understand relev inform respons specif question child dee use mix method design pilot gene compass evalu accept caregiv clinician feasibl impact caregiv	D017028;D004827	T098;T099;T033;T097;T047
36,288,835	muktwelv protocol phase ii randomis control open parallel group multicentr trial selinexor cyclophosphamid prednisolon scp versus cyclophosphamid prednisolon cp patient relaps refractori multipl myeloma multipl myeloma malign plasma cell around new case per year uk cyclophosphamid plus prednisolon consid standard care diseas symptom control advanc relaps refractori myeloma set within uk nhs select nuclear export inhibitor selinexor relat well toler previous clinic trial offer promis use combin wide rang anti cancer treatment investig addit selinexor improv respons cyclophosphamid plus prednisolon without ad prohibit toxic	D000971;D009101;D009364	T061;T191
36,288,834	gender represent authorship later phase system clinic trial biliari tract cancer btc retrospect review publish literatur femal physician medicin increas dispar femal authorship exist aim studi characteris factor associ femal first ff femal senior sf authorship later phase system oncolog clinic trial biliari tract cancer btc identifi chang time	D001319;D002986	T062;T057
36,288,833	rapid studi protocol cluster randomis feasibl trial midwif facilit intervent pregnant women symptom mild moder anxieti mani women experi symptom pregnanc elev prolong anxieti negat effect woman babi rapid intervent aim provid suitabl time support women mild moder anxieti rapid intervent base social support relat continu psycholog relax respons theori compris midwif facilit group discuss one one support direct self help materi	D008427;D008880	T058;T091;T097
36,288,832	effect covid pandem matern healthcar indic southern iran interrupt time seri analysi epidem anticip influenc coverag health servic assess impact covid pandem matern healthcar indic care provid perform	D000086382	T047;T067
36,288,831	ten session transcrani direct current stimul chronic chikungunya arthralgia studi protocol randomis clinic trial chikungunya virus infect still epidem brazil incid case per northeast region patient present relaps remit chronic arthralgia debilit pain last year transcrani direct current stimul tdcs appear promis novel neuromodul approach pain relat network allevi pain sever pain syndrom object evalu effect tdcs cfp montag pain muscl strength function qualiti life chronic arthralgia	D065632;D065908	T061;T047
36,288,830	prognost risk factor analysi nomogram construct primari liver cancer elder patient base seer databas evalu risk factor construct nomogram model prognosi primari liver cancer elder base data us seer databas	D049451;D008113	T081;T170;T191
36,288,829	comparison collater status defus dawn criteria patient select endovascular thrombectomi within hour stroke protocol meta analysi perfus imag accord defus dawn criteria appli select patient larg vascular occlus stroke undergo endovascular therapi evt extend time window emerg studi shown collater blood flow base criteria may effect defus dawn criteria evalu evt elig beyond hour conduct meta analysi compar collater status base criteria defus dawn criteria	D020521;D002545;D057510;D000083242	T061;T047;T046
36,288,828	first communic efficaci combin lutetium psma immunotherapi outsid prostat cancer prostat specif membran antigen psma target radioligand therapi valid treatment option patient advanc prostat cancer although psma express limit prostat tissu littl known relev type cancer present case report patient uterin leiomyosarcoma progress immunotherapi treat lu psma radionuclid therapi report first time lu psma radionuclid therapi combin immunotherapi outsid prostat cancer observ post treatment reduct tumor growth rate although notic diseas respons base recist criteria suggest lu psma treatment especi combin immunotherapi may option patient cancer without therapeut option insight lu psma radionuclid therapi consid tumor stain posit psma	D008187;D011471	T196;T191;T197
36,288,826	opsoclonus myoclonus paraneoplast syndrom nasopharyng carcinoma nasopharyng carcinoma present epistaxi cervic lymphadenopathi audiolog symptom secondari eustachian tube dysfunct pain neurolog symptom tumour direct invad skull base unusu patient present indirect system manifest paraneoplast neurolog syndrom preced clinic overt malign year therefor combin thorough clinic laboratori radiolog investig requir reach diagnosi intraven immunoglobulin steroid might improv neurolog symptom initi prevent irrevers neuron damag treatment under cancer import long term resolut case add small grow bodi literatur relat anti ri antibodi opsoclonus myoclonus syndrom present first report associ combin nasopharyng carcinoma	D053578;D010257;D009303	T047;T191
36,288,825	donut sign uniqu radiolog sign cerebr metastasi malign mesothelioma man present emerg depart day histori confus right facial droop diagnos stage iiib tnm malign mesothelioma month previous given palliat chemotherapi mri brain demonstr left pariet cerebr metastasi uniqu radiolog characterist term donut sign underw craniotomi complet macroscop resect lesion good postop outcom mesothelioma cerebr metastas rare report clinic entiti hand case report case seri avail mri often demonstr distinct thick wall lesion term donut sign may indic diagnosi furthermor case autopsi seri suggest metastas may underdiagnos clinic set due dismal prognosi newer effect neoplast treatment strategi emerg may rise incid central nervous system metastas futur	D000086002;D008654;D015173	T191
36,288,823	safeti efficaci sglt inhibitor dapagliflozin patient system lupus erythematosus phase iii trial sodium glucos cotransport inhibitor identifi profound renalcardiac protect effect differ diseas assess safeti efficaci dapagliflozin among adult patient system lupus erythematosus sle	D008180;D000077203;D003924;D008181	T121;T047;T109
36,288,822	postvaccin anti igg level predict anti sar cov neutralis activ week patient ra correl immun respons follow two dose regimen mrna anti sar cov vaccin patient rheumatoid arthriti ra develop potent neutralis antivir activ	D000086382;D001172	T047;T067
36,288,820	bioresorb vascular scaffold versus convent drug elut stent across time meta analysi randomis control trial bioresorb vascular scaffold bvs design reduc rate late advers event observ convent drug elut stent des dissolv restor last patenc	D054855;D062645;D003324;D009203;D013927	T061;T047;T074;T046
36,288,819	scale safeti qualiti improv intervent periop care systemat scope review implement strategi effect global billion peopl lack access safe surgic care death due lack qualiti care rather lack access mani proven qualiti improv qi intervent exist high incom countri implement lowmiddl incom countri lmic face challeng current theori driven systemat articul knowledg factor support success scale qi periop care set lack aim identifi periop safeti qi intervent appli scale lmic evalu implement mechan use implement theori	D058996;D006296	T058;T057
36,288,813	compar risk thrombosi thrombocytopenia syndrom thromboembol event associ differ covid vaccin intern network cohort studi five european countri us quantifi compar risk thrombosi thrombocytopenia syndrom thromboembol event associ use adenovirus base covid vaccin versus mrna base covid vaccin	D000086663;D013921;D013923;D013927	T200;T047;T046
36,288,809	food insecur diet qualiti suboptim diabet manag among us adult diabet healthi diet recommend support diabet manag includ hbac blood pressur cholesterol abc control food insecur barrier consum healthi diet determin preval food insecur diet qualiti among us adult diabet associ abc manag	D005523;D003920	T081;T047
36,288,808	impact packag health nutrit psychosoci support wash intervent deliv preconcept pregnanc earli childhood period birth outcom linear growth month age factori individu randomis control trial determin effect integr concurr deliveri health nutrit water sanit hygien wash psychosoci care intervent preconcept period alon pregnanc earli childhood throughout preconcept pregnanc earli childhood birth outcom linear growth month age compar routin care	D012499;D000067250	T061;T090;T058
36,288,806	patient safeti cultur associ factor secondari health care capit region denmark influenc specialti healthcar profess gender aim explor influenc healthcar profession hcps specialti profess gender length employ percept six dimens patient safeti cultur psc relat characterist two dimens safeti climat percept manag	D061214;D017751	T058;T080;T057
36,288,802	genom signatur mitonuclear coevolut mammal mitochondri mt nuclear encod protein integr aerob respir requir co function among gene product fundament differ genom differ evolutionari rate inherit mechan select pressur set stage incompat interact product two genom mitonuclear coevolut hypothesi posit incompat may avoid evolut one genom select complementari chang interact gene encod genom nuclear compens deleteri mtdna chang offset compensatori nuclear chang often invok primari mechan mitonuclear coevolut yet direct evid support nuclear compens rare use data mammalian speci repres eight order show strong correl evolutionari rate mt nuclear encod mt target n mt protein mt non mt target nuclear protein provid strong support mitonuclear coevolut across mammal n mt gene direct mt interact also show strongest correl although n mt gene elev dnds ratio compar mt gene predict nuclear compens n mt site close contact mt protein overrepres sign posit select compar noncontact n mt site contrari predict nuclear compens furthermor tempor pattern n mt mt amino acid substitut support predict nuclear compens even posit select function import residu direct mitonuclear contact overal result strong support mitonuclear coevolut across million year mammalian evolut fail support nuclear compens major mode mitonuclear coevolut	D004272;D050259	T045;T123;T028;T114
36,288,796	enhanc numeraci skill follow team base learn unit state pharmaci student longitudin cohort studi literatur suggest abil numer fulli understood without account social context mathemat activ repres team base learn tbl andragog approach theoret link sociocultur communiti practic learn studi aim quantit explor impact tbl instruct numeraci develop cohort pharmaci student identifi impact tbl instruct numeraci develop social perspect healthcar educ	D013339	T097
36,288,789	particip physic educ class relat physic activ sedentari behavior systemat review aim systemat review summar result assess methodolog qualiti studi analyz relat physic educ particip physic activ sedentari behavior schoolchildren	D057185;D015444	T033;T056;T079;T061
36,288,761	human papillomavirus ee contribut immun escap progress cervic cancer regul mir ppd l axi persist infect human papillomavirus hpv immun escap main caus cervic cancer ee encod hpv may close relat carcinogenesi hpv infect may upregul pd l express result immun escap cervic cancerigenesi evid indic mirna may mediat regul ee pd l therefor aim screen mirna verifi express function bioinformat approach use screen mirna mediat regul ee pd l express mirna pd l hpv hpv cervic cancer cell compar effect ee evalu effect mirna pd l assess gain loss function test final vivo experi conduct verifi effect mirna tumor growth surviv tumor bear mice six mirna screen mir p identifi mir p downregul pd l upregul hpv cell transfect e e ee rescu test show upregul mir p attenu effect ee pd l revers relationship pd l mir p confirm vivo experi suggest mir p upregul inhibit growth transplant tumor target pd l mir p act tumor suppressor cervic cancer hpv ee may promot immun escap cervic cancer cell regul mir ppd l axi use mir p tumor immunotherapi new strategi propos	D002583;D009856;D030361;D035683	T123;T116;T191;T114;T047
36,288,748	real time user feedback support clinic decis support system improv improv clinic decis support cds allow user provid real time feedback interact cds tool creat process respond act feedback	D020000	T058;T170
36,288,737	expositori discours product school age children across two scaffold task school age children encount expositori discours daili classroom skill understand product expositori languag critic academ success purpos studi compar children product two type expositori discours generat retel employ scaffold note take procedur assist children develop sampl twenti six typic develop children year age particip studi expositori generat task children gave explan favorit activ retel task view video provid explan inform video overal expositori generat sampl longer richer content expositori retel sampl demonstr greater lexic divers addit generat sampl contain fewer grammat error retel sampl trend measur syntact complex posit relat across task signific differ sampl type find suggest use scaffold procedur support expositori product result sampl long enough valid analysi children languag product utter averag longer report similar studi without scaffold potenti impact comprehens retel task perform discuss	D007804;D007802	T171;T041
36,288,736	build research initi develop group effort bridg patient partner aphasia research research initi research often littl input group affect result research aim project describ practic embrac patient partner ie individu aphasia spousesfamili member research six webinar develop research patient partner requir prior particip joint confer focus collabor research team confer design base appreci inquiri approach includ patient partner research prioriti plan accomplish across various health domain unit state first organ nation effort unit state support inclus peopl aphasia famili activ partner research process consequ hope futur aphasia research also includ patient partner team research process ecolog valid outcom	D001037	T047;T048
36,288,733	cross section analysi treatment pup germani first data gephard studi group initi treatment patient haemophilia remain challeng choic therapi time dose frequenc still intens debat new treatment option like novel factor concentr non factor therapi broaden discuss	D006467;D002836	T047
36,288,732	platelet sera donor convalesc plasma mild covid show procoagul phenotyp coronavirus diseas covid associ increas thromboembol complic long term alter coagul system acut covid infect still subject research furthermor effect sera convalesc subject platelet known studi investig platelet phenotyp coagul fibrinolysi covid convalesc plasma ccp donor analyz convalesc sera induc effect platelet investig ccp donor histori mild covid infect donor covid use control analyz phosphatidylserin ps extern cdp express glycoprotein vi gpvi shed platelet rich plasma prp incub wash healthi platelet donor sera use flow cytometri coagul fibrinolysi system assess thromboelastometri forti seven ccp donor male femal mean age sd year histori mild covid infect includ median durat acut covid infect day rang find increas ps extern cdp express gpvi shed platelet ccp donor sera ccp donor induc ps extern gpvi shed healthi platelet sera induc cdp express slight albeit statist signific lower ccp donor plasma donor without histori covid one patient show increas maximum clot firm prolong lysi time thromboelastometri find suggest procoagul platelet phenotyp present mild covid furthermor ccp sera affect activ status platelet	D000086382	T047;T067
36,288,729	founder event caus domin childhood epilepsi surviv year weak select pressur genet epilepsi febril seizur plus gef autosom domin famili epilepsi syndrom character distinct phenotyp heterogen within famili scnb cc g pcystrp variant identifi independ multi generat famili gef although variant present popul databas low frequenc strong clinic genet function evid support pathogen recurr variant may due founder event variant inherit common ancestor report evid singl founder event give rise scnb cc g variant independ famili epilepsi common haplotyp observ famili age recent common ancestor estim approxim year ago analysi uk biobank whole exom sequenc data identifi individu variant individu carri haplotyp match epilepsi affect famili suggest instanc variant deriv singl mutat event unusu find variant caus autosom domin earli onset diseas outbr popul persist mani generat attribut relat mild phenotyp carrier incomplet penetr founder event well establish autosom recess late onset disord rare observ earli onset autosom domin diseas find suggest variant present popul low frequenc consid potenti pathogen mild phenotyp incomplet penetr may import contributor genet landscap previous thought	D003294;D004827	T033;T047
36,288,726	neurobiolog long covid persist neurolog neuropsychiatr symptom affect substanti fraction peopl covid repres major compon post acut covid syndrom also known long covid review understood pathobiolog post acut covid impact cns discuss possibl neurobiolog underpin cognit symptom affect covid survivor propos chief mechan may contribut emerg neurolog health crisi	D000086382;D009422;D001523	T047;T067;T048
36,288,725	sar cov infect neuron induc neuroinflamm non human primat model covid sever acut respiratori syndrom coronavirus sar cov etiolog agent coronavirus diseas covid induc plethora neurolog complic patient howev still debat whether sar cov direct infect brain whether cns sequela result system inflammatori respons trigger peripheri use high resolut microscopi investig whether sar cov reach brain viral neurotrop modul age non human primat model covid seven day infect sar cov detect olfactori cortex interconnect region accompani robust neuroinflamm neuron damag exacerb age diabet anim studi provid initi framework identifi molecular cellular mechan under sar cov neurolog complic essenti reduc short long term burden covid	D000086382;D009422	T047;T067
36,288,724	tumor associ macrophag express transcript factor irf promot cell exhaust cancer tumor popul antigen present cell apc includ macrophag subset distinct origin function examin cancer impact mononuclear phagocyt apc murin model breast cancer tumor induc expans monocyt deriv tumor associ macrophag tam activ type dendrit cell dcs express requir transcript factor interferon regulatori factor irf although dcs mediat cytotox lymphocyt ctl prime tumor drain lymph node tam promot ctl exhaust tumor irf requir tam abil present cancer cell antigen tam specif irf delet prevent exhaust cancer cell reactiv ctls suppress tumor growth tumor patient immun infiltr renal cell carcinoma abund tam express irf enrich irf gene express signatur furthermor tam irf signatur co segreg ctl exhaust signatur across multipl cancer type thus ctl exhaust promot tam via irf	D002292;D007680	T191
36,288,719	mettl regul methyl ptch gli sonic hedgehog signal promot tumor progress shh medulloblastoma shh subgroup medulloblastoma shh mb one common malign pediatr tumor aris cerebellum previous show rna methyl particip regul cerebellar develop investig whether dysregul methyl contribut tumorigenesi shh mb show high express methyltransferas mettl associ wors surviv patient shh mb larg number hypermethyl transcript identifi shh mb tumor cell seq find mettl promot tumor progress via activ sonic hedgehog signal mechanist mettl methyl ptch gli rnas regul rna stabil translat import target mettl deplet mettl express treatment catalyt inhibitor stm restrain tumor progress collect studi show critic function mettl methyl shh mb indic potenti role mettl therapeut target shh mb	D002528;D008527	T191
36,288,718	critic development window elavhu depend mrna signatur onset neuron differenti cell type specif gene regulatori program essenti cell differenti function anim neuron high conserv elavhu famili protein promot altern splice polyadenyl mrna precursor creat uniqu neuron transcript isoform assess transcriptom profil neurogenesi success drosophila model engin express differ level elav activ cours develop show elav mediat establish subset neuron mrna isoform onset neuron differenti constitut development bottleneck overcom later nuclear activ paralog found neuron fne loss elav function outsid critic time window result neurolog defect find fne activ earli enough restor elav depend neuron mrna isoform fulli rescu develop find demonstr essenti role robust cellular strategi maintain elav activ intact neuron signatur neurogenesi neuron function	D029721	T123;T116
36,288,717	modif confer thermal vulner hpv e oncotranscript via revers regul reader protein igfbp upon heat stress human papillomavirus hpv induc carcinogenesi critic depend viral earli protein e make e attract therapeut target report e messeng rna mrna contain oncotranscript complex select target heat treatment hpv infect cell viral e mrna modifi n methyladenosin stabil igfbp cellular reader heat treatment downregul e mrna protein destabil igfbp without involv canon heat shock protein revers hpv associ carcinogenesi vitro vivo mechanist heat treatment promot igfbp aggreg presenc modifi e mrna form distinct heat induc e mrna igfbp granul resolv ubiquitin proteasom system collect result show mutual regul rna reader also provid heat treatment base therapeut strategi hpv associ malign specif downregul e mrna igfbp oncogen complex	D052685;D030361	T005;T047
36,288,716	isoform specif inhibit fgfr signal achiev de novo design mini protein cellular signal fibroblast growth factor receptor fgfrs high regul process mediat specif interact distinct subset fibroblast growth factor fgf ligand two fgfr isoform generat altern splice epitheli b mesenchym c isoform investig properti mini protein mb develop silico design strategi bind ligand bind region fgfr describ structur biophys cellular analys demonstr mb bind high affin c isoform fgfr result inhibit cellular signal induc subset fgfs preferenti activ c isoform fgfr notabl mb block interact fgfr klotho protein function antagonist metabol hormon fgf fgf provid mechanist insight strategi develop therapeut diseas driven aberr activ fgfrs	D017468;D005346	T123;T116;T192
36,288,715	target rtnnogo receptor reduc level al protein ataxin gene base therapeut strategi lower ataxin level emerg neurodegen diseas amyotroph later sclerosi al spinocerebellar ataxia type sca addit strategi lower level ataxin could benefici perform genom wide array small interf rna sirna screen human cell identifi rtnr gene encod rtnnogo receptor potent modifi ataxin level rtnr knockdown treatment peptid inhibitor suffici lower ataxin protein level mous human neuron vitro rtnr knockout mice reduc ataxin level vivo provid evid ataxin share role rtnnogo receptor limit axon regener reduct either protein increas axon regrowth follow axotomi data defin rtnnogo receptor novel therapeut target al sca implic target ataxin potenti treatment follow nerv injuri	D000690;D020754	T047
36,288,714	genom wide crispr screen reveal v atpas drug target lower level al protein ataxin mutat ataxin gene atxn caus neurodegen disord amyotroph later sclerosi al spinocerebellar ataxia type sca therapeut strategi use antisens oligonucleotid target atxn enter clinic trial human addit way decreas ataxin level could lead cheaper less invas therapi elucid ataxin normal regul perform genom wide fluoresc activ cell sort fac base crispr cas screen human cell identifi gene encod compon lysosom vacuolar atpas v atpas modifi endogen ataxin protein level multipl fda approv small molecul v atpas inhibitor lower ataxin protein level mous human neuron oral administr least one drug etidron suffici decreas ataxin brain mice togeth propos v atpas drug target al sca demonstr valu fac base screen identifi genet potenti druggabl modifi human diseas protein	D000690;D025262;D020754	T047;T126;T116
36,288,713	elev pentos phosphat pathway flux support appendag regener fundament step regener rapid growth replac lost tissu cell must generat suffici lipid nucleotid protein fuel rapid cell divis defin metabol pathway under regen growth undertak multimod investig metabol reprogram xenopus tropicali appendag regener regener tissu increas glucos uptak howev inhibit glycolysi decreas regener instead glucos funnel pentos phosphat pathway ppp essenti full tail regener liquid chromatographi mass spectrometri lc ms metabolit profil reveal increas nucleotid nicotinamid intermedi requir cell divis use singl cell rna sequenc scrna seq find high prolif cell increas transcript ppp enzym glycolyt enzym ppp inhibit result decreas cell divis specif regener tissu result inform model wherein regener tissu direct glucos toward ppp yield nucleotid precursor drive regen cell prolifer	D010427;D006019	T044
36,288,712	locus coeruleus mediat behavior flexibl behavior flexibl abil adjust behavior strategi respons chang environment conting major hypothesi field posit activ neuron locus coeruleus lc play import role mediat behavior flexibl test hypothesi develop tactil base rule shift detect task mice respond left right whisker deflect context depend manner exhibit vari degre switch behavior record spike activ optogenet tag neuron lc millisecond precis task perform reveal promin grade correl baselin lc activ behavior flexibl higher baselin activ follow rule chang associ faster behavior switch new rule increas baselin lc activ optogenet activ acceler task switch improv task perform overal studi provid import evid reveal link lc activ behavior flexibl	D008125;D062308	T063;T023
36,288,711	express mosquito mirna entomopathogen fungus induc pathogen mediat host rna interfer increas fungal efficaci grow threat insecticid resist prompt urgent need develop addit tool mosquito control entomopathogen fungi provid eco friend altern chemic insecticid one limit use mycoinsecticid relat low virul report approach suppress mosquito immun increas fungal virul engin beauveria bassiana express aed immunosuppress microrna mirna induc host rna interfer rnai immun respons show engin strain produc deliv mirna host cell activ cross kingdom rnai infect suppress mosquito immun target multipl host gene therebi dramat increas fungal virul aed aegypti galleria mellonella larva import express host mirna also signific increas fungal virul insecticid resist mosquito creat potenti insecticid resist manag pathogen mediat rnai pmrnai base approach provid innov strategi enhanc efficaci fungal insecticid elimin likelihood resist develop	D007306;D035683;D000330;D052982	T123;T131;T004;T204;T114
36,288,710	later septum modul cortic state tune respons threat stimuli sudden unexpect environment chang captur attent perceiv potenti danger evok defens behavior state perturb later septum ls produc extrem hyperdefens even innocu stimuli structur influenc stimulus evok defens respons threat percept remain unclear show crhr express neuron mous ls exhibit phasic activ upon detect threaten reward stimuli threat stimulus driven activ predict probabl vigor type defens behavior evok although necessari suffici potenti stimulus trigger defens respons ls crhr neuron promot specif behavior rather stimul elicit negat valenc physiolog arous moreov ls crhr activ track brain state fluctuat drive cortic activ rapid awaken absenc threat togeth find suggest ls direct bottom modul cortic function evok preparatori defens intern state select enhanc respons threat relat stimuli	D005239;D009474	T025;T041
36,288,709	cholinerg control striatal gabaerg microcircuit cholinerg interneuron cin essenti element striatal circuit function although acetylcholin signal via muscarin receptor machr well studi recent data indic postsynapt nicotin receptor nachr locat striatal gabaerg interneuron gin equal critic one exampl cin stimul induc larg disynapt inhibit striatal project neuron spns mediat nachr activ gin although circuit ideal posit modul striatal output neuron involv definit identifi incomplet map cin gin interconnect show cin modul four gin popul via intric mechan involv co activ presynapt postsynapt machr nachr use optogenet demonstr particip tyrosin hydroxylas express gin disynapt inhibit spns via heterotyp electr coupl neurogliaform interneuron altogeth result highlight import cin regul gin microcircuit via complex synapticheterosynapt mechan	D000109;D011978	T123;T121;T116;T192;T109
36,288,708	mtor larp depend regul top mrna poli tail ribosom load translat termin oligopyrimidin top mrnas encod protein synthesi machineri strict regul amino acid sens mtor pathway howev regulatori mechan remain elus demonstr top mrna translat posit correl poli tail length mtor activeamino acid rich condit suggest top mrnas post transcript control poli tail length regul consist tail length top mrnas dynam fluctuat respons amino acid avail poli tail shorten mtor activeamino acid rich condit wherea long tail top mrnas accumul mtor inactiveamino acid starv aa condit rna bind protein larp indispens process larp interact non canon poli polymeras induc post transcript polyadenyl target find illustr larp contribut select accumul top mrnas long poli tail aa result acceler ribosom load onto top mrnas resumpt translat aa	D012261;D001324	T129;T123;T116

36,288,892

initi experi atezolizumab plus bevacizumab unresect hepatocellular carcinoma real world retrospect studi current studi evalu efficaci toxic atezolizumab plus bevacizumab patient advanc stage hepatocellular carcinoma real world set

D006528;D008113

T191

36,288,891

efficaci adjuv chemotherapi follow curat resect colorect cancer liver metastas routin use adjuv chemotherapi ac follow hepatectomi colorect liver metastas crlm univers practic lack support evid therefor investig efficaci ac follow curat crlm resect

D015179;D008113

T191

36,288,890

clinic impact primari cancer patient receiv curat treatment esophag cancer present studi evalu clinic impact metachron synchron primari cancer opc patient receiv curat treatment esophag cancer

D009378;D016609;D004938

T191

36,288,889

vascular non vascular fibula graft tumour reconstruct singl centr experi mid long term result vascular vfg non vascular fibula graft nvfg use reconstruct bone defect tumour resect studi compar autograft result risk factor complic

D019651;D001859

T061;T191

36,288,888

pan aurora kinas inhibitor danusertib induc apoptosi epstein barr virus transform b cell caspas endoplasm reticulum stress signal evid relev epstein barr virus ebv various type cancer expand howev definit mechan ebv induc oncogenesi remain ambigu purpos studi identifi relev aurora kinas ebv induc carcinogenesi cellular respons danusertib pan aurora kinas inhibitor under signal mechan ebv transform b cell also investig

D020031;D004854;D001402

T047;T005;T025

36,288,887

engulf cell motil elmo regul tumor cell behavior predict prognosi colorect cancer engulf cell motil elmo play crucial role process migrat chemotaxi metastasi tumor cell elmo implic pathogenesi various cancer howev distinct function elmo colorect cancer crc unclear determin whether elmo affect oncogen behavior crc cell investig prognost valu crc patient

D019938;D015179

T123;T191;T116

36,288,886

chang serum trace element concentr surgeri resect breast cancer miner trace element tes play vital role normal biolog function cancer breast carcinoma common occur cancer women aim studi evalu chang te level breast cancer surgeri clinic util reliabl te level assay use induct coupl plasma mass spectrometri icp ms

D002285;D001943;D018270;D014131;D012643

T121;T123;T196;T191

36,288,885

ptx treatment colon cancer mode action base tumor marker cytokin kinet cancer progress associ signific cachexia induc weight loss stomat pentoxifyllin ptx drug shown benefici anti inflammatori effect cancer patient main anti tnf mechan studi determin ptx effect mode action weight loss stomat surviv colon cancer patient treat chemotherapi examin kinet tumor marker cytokin level

D003110;D010431;D013280

T121;T047;T191;T109

36,288,884

signific chrp p delet cancer develop pan cancer silico analysi delet chrp locus relat develop sever type cancer main due presenc cdkna cdknb gene howev sever gene region potenti import tumorigenesi therefor aim analyz silico potenti prognost signific alter copi number express gene present chrp locus tcga dataset approxim patient

D000230;D010190;D002292;D005909;D005910;D007680

T191

36,288,883

interleukin il cytokin serum concentr correl pain score number analges dose follow surgeri anti proinflammatori cytokin plasma high sensit c reactiv protein hs crp use assess inflammatori stress respons isr follow surgeri howev serum il interleukin cytokin valu versus numer rate scale nrs pain score number analges dose nad postop unknown

D016207;D020382;D010149

T129;T047;T116;T184

36,288,882

contribut matrix metalloproteinas promot genotyp hepatocellular carcinoma suscept metalloproteinas mmp previous found regul hepatocellular carcinoma hcc specimen cell favor epitheli mesenchym transit howev contribut mmp genotyp hcc reveal date studi aim evalu contribut mmp promot g rs c rs genotyp risk hcc taiwan hcc incid extrem high compar worldwid data

D006528;D008113

T191

36,288,881

signific contribut interleukin genotyp childhood acut lymphocyt leukemia risk taiwanes evid shown interleukin il antitumor pro tumor effect various type leukemia current studi aim investig contribut il polymorph risk childhood acut lymphocyt leukemia taiwan

D020382;D054198

T129;T191;T116

36,288,880

molecular characterist immunogenom profil cholangioblast variant intrahepat cholangiocarcinoma year old patient cholangioblast variant intrahepat cholangiocarcinoma cvicc exceed rare primari biliari tract tumor typic occur young patient median age year old mimic metastat well differenti neuroendocrin tumor liver similar histolog immunophenotyp featur

D018281;D008113;D001650

T191

36,288,879

clinic impact nutrit inflamm assess tool gastric cancer treatment standard treatment gastric cancer surgic resect periop adjuv treatment multidisciplinari treatment gastric cancer lead nutrit inflammatori chang nutrit inflammatori chang multidisciplinari treatment lead poor physic activ sever toxic patient receiv chemotherapi radiat therapi poor oncolog outcom evalu periop nutrit inflammatori status treatment necessari order util optim multidisciplinari therapi gastric cancer physician abl detect periop nutrit inflammatori status gastric cancer treatment would abl select optim treatment periop nutrit treatment recent various type nutrit inflamm assess tool develop report gastric cancer nutrit inflamm assess tool clinic advantag eas implement periop access low cost hand tool clinic characterist must understood use clinic practic review summar background current status futur perspect applic nutrit inflamm assess tool gastric cancer treatment

D013274

T191

36,288,878

high express cd aldha predict poor prognosi basal like breast cancer cd immun adhes molecul cellular surfac previous found high express cd predict poor prognosi patient lower grade glioma therefor aim paper investig associ cd breast cancer

D001943

T191

36,288,877

candid oncogen arhgap nos orb develop scirrhous type gastric cancer scirrhous type gastric cancer sgc one intract cancer subtyp character rapid cancer cell prolifer infiltr accompani extens stromal fibrosi one reason poor prognosi may lack molecular target drug sgc unknown driver gene explor somat mutat human sampl sgc use next generat sequenc ngs hamper abund fibrous tissu sampl therefor studi aim determin novel oncogen rna sequenc use sgc cell line avoid contamin fibrosi

D002293;D013274

T191

36,288,876

establish characteris human clear cell sarcoma malign melanoma cell line clear cell sarcoma soft tissu ccsst convent malign melanoma mm rare aggress tumour similar morpholog express melanocyt marker

D018227;D008545

T191

36,288,875

oral recombin methioninas combin rapamycin erad osteosarcoma breast patient deriv orthotop xenograft mous model primari osteosarcoma breast rare malign share histolog featur osteosarcoma also high sensit methionin restrict due methionin addict previous establish patient deriv orthotop xenograft pdox nude mous model deriv tumor tissu patient primari mammari osteosarcoma present studi investig efficaci oral recombin methioninas rmetas combin rapamycin inhibitor mammalian target rapamycin mtor kinas mammari osteosarcoma pdox nude mous model

D001859;D012516

T191

36,288,874

determin clonogen radiosensit hela cell earli late g phase use fluoresc ubiquitin base cell cycl indic fucci recent report post irradi hela cell micronuclei frequenc increas earli g phase comparison late g phase inconsist result well recogn studi use clonogen assay studi determin radiosensit cell use clonogen assay make best use fucci properti simultan character cell cycl kinet dna damag respons

D011836

T032

36,288,873

surgeri limb edema health relat qualiti life prospect follow studi patient cutan malign melanoma latest develop oncolog therapi malign melanoma discoveri complet lymph node dissect offer surviv benefit chang landscap melanoma surgeri need inform health relat qualiti life hrqol consequ melanoma surgeri

D011788;D008545

T078;T191

36,288,872

evalu neoadjuv chemotherapi lower esophag squamous cell carcinoma measur esophag wall thick aim studi evalu efficaci preoper chemotherapi stage ii iii esophag squamous cell carcinoma base object comput tomographi method

D000077277;D004938

T191

36,288,871

pre postop circul tumour dna patient gastrointestin stromal tumour methodolog assess studi gastrointestin stromal tumour gist harbour genet aberr receptor tyrosin kinas kit kit platelet deriv growth factor receptor pdgfra patient circul tumour dna ctdna potenti biomark patient gist previous studi investig ctdna around surgeri patient gist present diverg result regard proport patient detect ctdna studi aim investig feasibl detect monitor ctdna pre postop compar two differ circul free dna cfdna extract method valid result obtain next generat sequenc ngs use real time pcr technolog

D046152;D000074141;D000073888

T123;T191;T114

36,288,870

impact knowledg base plan model improv plan complex deliver vmat prostat cancer multi institut studi studi evalu impact knowledg base plan kbp model improv plan complex deliveri accuraci volumetr modul arc therapi vmat prostat cancer multipl institut

D050397;D011471

T061;T191

36,288,869

develop novel small antitumor compound inhibit pd pd l bind anti program death pd pd ligand pd l antibodi success treatment patient solid cancer howev sever disadvantag need resolv oral small molecul anti pd pd l inhibitor develop good bioavail

D060890;D009369

T129;T191;T116

36,288,868

gustav roussi immun score predict postop complic non cancer death elder patient colon cancer gustav roussi immun grim score aa prognost marker various cancer type aim studi investig relationship grim score short long term outcom elder patient colon cancer

D009364;D003110

T191

36,288,867

effect cyclooxygenas canin melanoma deriv extracellular vesicl tumor microenviron vitro tumor cell deriv extracellular vesicl tev promot tumor growth metastasi thus drawn attent research tev regul tumor microenviron facilit crosstalk immun stromal cell macrophag one key compon involv malign behavior melanoma general activ macrophag polar pro inflammatori anti inflammatori pro tumor phenotyp howev role canin melanoma deriv ev macrophag polar elus studi aim analyz pro anti inflammatori cytokin common marker macrophag vitro

D000067128;D008545

T026;T191

36,288,866

associ high gene express variant chymas increas risk basal cell carcinoma previous studi associ certain variat gene encod factor renin angiotensin system ras indirect lead higher angiotensin ii angii level greater risk basal cell carcinoma bcc develop chymas cma main regul ras independ angii generat pathway numer studi shown oncogen potenti sever cancer type includ bcc studi investig possibl associ bcc pathogenesi function dna polymorph ag rs affect express cma gene

D002280;D012878

T191

36,288,865

thyroglobulin level predictor papillari cancer recurr thyroid lobectomi effect use serum thyroglobulin tg predict thyroid cancer recurr thyroid lobectomi unknown studi aim evalu predict natur serum tg tg trend thyroid lobectomi

D013954;D013964

T125;T121;T191;T116

36,288,864

clinicopatholog character primari diffus larg b cell lymphoma central nervous system primari central nervous system diffus larg b cell lymphoma cns dlbcl rare entiti account intracrani neoplasm studi aim investig clinicopatholog characterist primari cns dlbcl patient prognost implic

D016403;D016543

T191

36,288,863

surviv score elder patient brain metastas assign stereotact radiosurgeri fraction stereotact radiotherapi elder patient may benefit individu treatment surviv score creat patient age receiv radiosurgeri fraction stereotact radiotherapi brain metastas

D016634;D001932

T061;T191

36,288,862

neoadjuv therapi patient non small cell lung cancer complic chest wall invas multidisciplinari treatment includ anatom pulmonari chest wall resect recommend lung cancer complic chest wall invas present studi aim investig surviv benefit safeti preoper therapi follow surgeri non small cell lung cancer chest wall invas

D002289;D035441;D008175

T023;T191

36,288,861

letermovir prophylaxi cmv reactiv allogen stem cell recipi retrospect singl center analysi cytomegalovirus cmv reactiv one clinic signific complic allogen stem cell recipi frequent caus transplant relat mortal letermovir newli avail recent approv drug cmv prophylaxi retrospect singl center analysi investig benefit letermovir cmv prophylaxi allogen stem cell recipi

D003586;D018380

T061;T047

36,288,860

prognost signific nodal ratio number posit node patient squamous cell carcinoma head neck lymph node status high prognost relev head neck squamous cell carcinoma hnscc studi aim address hypothesi number posit node nodal ratio prognost impact surviv hnscc

D006258;D002294

T191

36,288,859

inhibit stat promot effector cell infiltr also immunosuppress hcc tumor microenviron stat involv progress sever cancer propos target therapi inde multitarget tyrosin kinas inhibitor drug regorafenib indirect inhibit stat signific enhanc effect anti program death receptor pd therapi hepatocellular carcinoma hcc model studi impact direct stat inhibitor tumor microenviron pd blockad efficaci hcc model

D006528;D008113;D013601

T191;T025

36,288,858

effect palliat care decis use hospit servic pancreat cancer patient retrospect studi continu chemotherapi use hospit servic near end life eol delay approach palliat care pc servic factor impair qualiti life near eol

D009369;D013727;D010190

T058;T191

36,288,857

prognost role porphyromona gingivali gingipain rgp matrix metalloproteinas oropharyng squamous cell carcinoma oral bacteria involv develop periodont alter tissu condit modifi immun respons way may also influenc tumor develop investig preval r gingipain rgp key virul factor oral pathobiont porphyromona gingivali tissu destruct enzym matrix metalloproteinas mmp mmp unselect consecut oropharyng squamous cell carcinoma opscc sampl investig relationship factor human papillomavirus hpv status treponema denticola chymotrypsin like proteinas td ctlp immunoexpress clinic paramet patient outcom

D030361;D009959;D006258

T047;T191

36,288,856

manag resist post transplant lymphoprolif disord car new option review therapeut option resistantrefractori post transplant lymphoprolif disord ptld relat chimer antigen receptor cell car therapi number possibl futur strategi treatment ptld follow method implement real world practic anti pd therapi checkpoint inhibitor nivolumab new anti cd ofatumumab brentuximab vedotin zanubrutinib howev innov method individu case success treatment rituximab resist epstein barr virus ebv ptld patient report far car innov method treatment base genet modif receptor autolog lymphocyt creat live drug therapi potent resist ptld lymphoprolifer b lymphocyt publish real world data patient treat car ptld indic success rate develop innov method treatment resistantrefractori ptld high rate resolut car therapi

D020031;D000076962;D008232

T129;T116;T192;T191;T047

36,288,855

hispan vs caucasian raceethn adrenocort carcinoma patient primari adrenocort carcinoma acc hispan raceethn may predispos higher stage initi diagnosi may result wors surviv test associ hispan raceethn cancer specif mortal csm acc patient addit test differ caus mortal ocm rate hispan caucasian

D018268;D000310;D000306

T191

36,288,854

suppress g protein coupl estrogen receptor gper enhanc anti invas efficaci select er agonist g protein coupl estrogen receptor gper often express tripl negat breast cancer tnbc gper respons mani non genom membran initi effect estrogen therefor analyz effect gper knockdown use specif sirna

D006528;D008113;D064726

T191

36,288,853

distress score cours radiotherapi pilot studi mani cancer patient receiv radiotherapi may caus distress pilot studi evalu distress level radiotherapi contribut design prospect trial

D009369;D000079225

T191;T048

36,288,852

potenti util mallampati score predict treatment complianc safeti profil patient head neck cancer undergo definit concurr chemoradiotherapi restrict mouth open rmo common manifest head neck cancer hnc poor prognost factor follow concurr chemoradiotherapi ccrt patient studi aim explor whether mallampati score visual assess distanc tongu base roof mouth use surrog rmo predict treatment outcom patient hnc undergo ccrt

D010984;D006258

T196;T191

36,288,851

prostaglandin dehydrogenas inhibit enhanc colon cancer metastasi regul epitheli mesenchym transit gene death colon cancer due metastasi recent pge found influenc colon cancer invas metastasi pgdh enzym metabol pge known tumor suppressor colon carcinogenesi studi investig effect pgdh colon cancer metastasi

D003110;D008113

T191

36,288,850

rechalleng lenvatinib atezolizumab plus bevacizumab treatment hepatocellular carcinoma atezolizumab plus bevacizumab lenvatinib key drug current system chemotherapeut regimen hepatocellular carcinoma hcc studi report potenti effect lenvatinib introduct atezolizumab plus bevacizumab treatment howev therapeut effect lenvatinib rechalleng atezolizumab plus bevacizumab treatment remain unclear

D006528;D008113

T191

36,288,849

luminophor chemistri detect urinari bladder cancer comparison cytolog urinari rapid test bta stat nmp bladderchek ubc rapid test new luminometr chelat develop detect urinari bladder cancer compar cytolog urinari rapid test bta stat nmp bladderchek ubc rapid test

D002295;D001749

T191

36,288,848

signific stage laparoscopi detect radiolog occult periton carcinomatosi gastric cancer gastric outlet obstruct consider optim treatment approach gastric cancer gastric outlet obstruct goo general found advanc stage unfavor prognosi studi perform examin preval radiolog occult periton carcinomatosi goo determin optim treatment strategi

D013274;D010534;D017219;D010535

T060;T047;T191;T061

36,288,847

detect recurr primari treatment oropharyng carcinoma post treatment surveil patient squamous cell oropharyng carcinoma scopc consist routin follow visit year suggest program ineffici find recurr increas surviv primari studi object investig recurr treatment scopc detect ie routin follow visit patient initi visit incident secondari object investig whether year surviv diagnosi recurr depend manner detect

D009959;D002294

T191

36,288,846

intravascular administr acridin orang zoledron bone metastasi model breast cancer studi evalu effect haematogen administr acridin orang ao alon combin zoledron zol bone metastas

D050071;D001859;D010014;D001943

T121;T191;T046

36,288,845

vater papilla preserv strategi advanc hepatocellular carcinoma excess bile duct tumor thrombus hepatocellular carcinoma hcc bile duct tumor thrombus bdtt high malign therefor continu multidisciplinari treatment essenti

D006528;D008113;D016461;D001650;D013927

T061;T191;T046

36,288,844

depress older adult covid pandem systemat review protocol depress common mental disord major caus year live disabl covid pandem caus increas preval depress worldwid aim identifi synthesis determin depress diagnost assess tool use evalu depress intervent carri sinc begin covid pandem popul age older

D000086382;D001523

T047;T067;T048

36,288,843

effect dri needl intervent lower limb dysfunct stroke studi protocol randomis control trial lower limb dysfunct among common sequela patient poststrok often result reduct qualiti life studi aim assess short interim term efficaci dri needl dn intervent lower extrem function balanc gait lower limb dysfunct stroke

D000071939;D000079245;D020521

T061;T047

36,288,842

prospect multicentr italian pregnanc cohort studi simpl associ matern first trimest simpl nutrit score earli placent function marker pregnanc outcom current adher nutrit guidelin low alarm rate obes worldwid micronutri defici document even industrialis countri consequ nutrit screen counsel repres critic subject earli pregnanc aim improv pregnanc outcom popul health

D011266;D018997

T125;T126;T116

36,288,841

fetal neonat matern pregnanc outcom women rheumatoid arthriti popul base cohort studi rheumatoid arthriti ra may advers influenc pregnanc lead advers birth outcom studi estim risk advers fetal neonat matern pregnanc outcom women ra

D001172;D011256

T033;T047

36,288,840

adapt popul health intervent new context qualit interview understand experi practic challeng research funder journal editor research adapt popul health intervent implement new context rapid expand accompani recent increas number framework guidanc support adapt process nevertheless remain limit explor real world experi undertak intervent adapt notabl challeng encount differ group stakehold manag understand experi imper ensur guidanc support adapt practic util qualit studi examin research stakehold experi fund conduct report adapt research

D000075485

T058

36,288,839

vulner popul malaria indoor residu spray withdrawn area use previous sustain protocol systemat review proven effect indoor residu spray ir malaria vector control strategi form one reliabl vector control strategi especi least popul cover howev date uncertainti regard consequ ir withdraw malaria control clear exit strategi place therefor need comprehens updat literatur regard malaria burden indic ir withdrawn follow sustain use

D008288;D000852

T047;T204

36,288,838

cohort profil swedish matern microbiom project swemami assess dynam associ microbiom matern neonat advers event swedish matern microbiom swemami project initi better understand dynam microbiom pregnanc longitudin microbiom sampl shotgun metagenom extens questionnair health registri linkag

D047928;D064307

T001;T032;T046;T028

36,288,837

cross section survey mental health addict effect servic impact care need children youth famili covid pandem covid masc studi protocol covid pandem tremend negat effect mental health well canadian mental health challeng especi acut among vulner canadian popul peopl live canada popul provinc ontario spent prolong time lockdown public health measur gap understand impact mental health system protocol describ mental health addict servic care studi use repeat cross section design examin effect impact need ontario adult covid pandem

D058873;D000086382

T047;T067

36,288,836

accept feasibl onlin inform linker servic caregiv child genet epilepsi mix method pilot studi protocol development epilept encephalopathi dee rare epilepsi condit collect impact children high genet heterogen result signific barrier accur adequ inform caregiv lead increas distress dissatisfact healthcar system address gap develop gene compass provid caregiv highest qualiti possibl understand relev inform respons specif question child dee use mix method design pilot gene compass evalu accept caregiv clinician feasibl impact caregiv

D017028;D004827

T098;T099;T033;T097;T047

36,288,835

muktwelv protocol phase ii randomis control open parallel group multicentr trial selinexor cyclophosphamid prednisolon scp versus cyclophosphamid prednisolon cp patient relaps refractori multipl myeloma multipl myeloma malign plasma cell around new case per year uk cyclophosphamid plus prednisolon consid standard care diseas symptom control advanc relaps refractori myeloma set within uk nhs select nuclear export inhibitor selinexor relat well toler previous clinic trial offer promis use combin wide rang anti cancer treatment investig addit selinexor improv respons cyclophosphamid plus prednisolon without ad prohibit toxic

D000971;D009101;D009364

T061;T191

36,288,834

gender represent authorship later phase system clinic trial biliari tract cancer btc retrospect review publish literatur femal physician medicin increas dispar femal authorship exist aim studi characteris factor associ femal first ff femal senior sf authorship later phase system oncolog clinic trial biliari tract cancer btc identifi chang time

D001319;D002986

T062;T057

36,288,833

rapid studi protocol cluster randomis feasibl trial midwif facilit intervent pregnant women symptom mild moder anxieti mani women experi symptom pregnanc elev prolong anxieti negat effect woman babi rapid intervent aim provid suitabl time support women mild moder anxieti rapid intervent base social support relat continu psycholog relax respons theori compris midwif facilit group discuss one one support direct self help materi

D008427;D008880

T058;T091;T097

36,288,832

effect covid pandem matern healthcar indic southern iran interrupt time seri analysi epidem anticip influenc coverag health servic assess impact covid pandem matern healthcar indic care provid perform

D000086382

T047;T067

36,288,831

ten session transcrani direct current stimul chronic chikungunya arthralgia studi protocol randomis clinic trial chikungunya virus infect still epidem brazil incid case per northeast region patient present relaps remit chronic arthralgia debilit pain last year transcrani direct current stimul tdcs appear promis novel neuromodul approach pain relat network allevi pain sever pain syndrom object evalu effect tdcs cfp montag pain muscl strength function qualiti life chronic arthralgia

D065632;D065908

T061;T047

36,288,830

prognost risk factor analysi nomogram construct primari liver cancer elder patient base seer databas evalu risk factor construct nomogram model prognosi primari liver cancer elder base data us seer databas

D049451;D008113

T081;T170;T191

36,288,829

comparison collater status defus dawn criteria patient select endovascular thrombectomi within hour stroke protocol meta analysi perfus imag accord defus dawn criteria appli select patient larg vascular occlus stroke undergo endovascular therapi evt extend time window emerg studi shown collater blood flow base criteria may effect defus dawn criteria evalu evt elig beyond hour conduct meta analysi compar collater status base criteria defus dawn criteria

D020521;D002545;D057510;D000083242

T061;T047;T046

36,288,828

first communic efficaci combin lutetium psma immunotherapi outsid prostat cancer prostat specif membran antigen psma target radioligand therapi valid treatment option patient advanc prostat cancer although psma express limit prostat tissu littl known relev type cancer present case report patient uterin leiomyosarcoma progress immunotherapi treat lu psma radionuclid therapi report first time lu psma radionuclid therapi combin immunotherapi outsid prostat cancer observ post treatment reduct tumor growth rate although notic diseas respons base recist criteria suggest lu psma treatment especi combin immunotherapi may option patient cancer without therapeut option insight lu psma radionuclid therapi consid tumor stain posit psma

D008187;D011471

T196;T191;T197

36,288,826

opsoclonus myoclonus paraneoplast syndrom nasopharyng carcinoma nasopharyng carcinoma present epistaxi cervic lymphadenopathi audiolog symptom secondari eustachian tube dysfunct pain neurolog symptom tumour direct invad skull base unusu patient present indirect system manifest paraneoplast neurolog syndrom preced clinic overt malign year therefor combin thorough clinic laboratori radiolog investig requir reach diagnosi intraven immunoglobulin steroid might improv neurolog symptom initi prevent irrevers neuron damag treatment under cancer import long term resolut case add small grow bodi literatur relat anti ri antibodi opsoclonus myoclonus syndrom present first report associ combin nasopharyng carcinoma

D053578;D010257;D009303

T047;T191

36,288,825

donut sign uniqu radiolog sign cerebr metastasi malign mesothelioma man present emerg depart day histori confus right facial droop diagnos stage iiib tnm malign mesothelioma month previous given palliat chemotherapi mri brain demonstr left pariet cerebr metastasi uniqu radiolog characterist term donut sign underw craniotomi complet macroscop resect lesion good postop outcom mesothelioma cerebr metastas rare report clinic entiti hand case report case seri avail mri often demonstr distinct thick wall lesion term donut sign may indic diagnosi furthermor case autopsi seri suggest metastas may underdiagnos clinic set due dismal prognosi newer effect neoplast treatment strategi emerg may rise incid central nervous system metastas futur

D000086002;D008654;D015173

T191

36,288,823

safeti efficaci sglt inhibitor dapagliflozin patient system lupus erythematosus phase iii trial sodium glucos cotransport inhibitor identifi profound renalcardiac protect effect differ diseas assess safeti efficaci dapagliflozin among adult patient system lupus erythematosus sle

D008180;D000077203;D003924;D008181

T121;T047;T109

36,288,822

postvaccin anti igg level predict anti sar cov neutralis activ week patient ra correl immun respons follow two dose regimen mrna anti sar cov vaccin patient rheumatoid arthriti ra develop potent neutralis antivir activ

D000086382;D001172

T047;T067

36,288,820

bioresorb vascular scaffold versus convent drug elut stent across time meta analysi randomis control trial bioresorb vascular scaffold bvs design reduc rate late advers event observ convent drug elut stent des dissolv restor last patenc

D054855;D062645;D003324;D009203;D013927

T061;T047;T074;T046

36,288,819

scale safeti qualiti improv intervent periop care systemat scope review implement strategi effect global billion peopl lack access safe surgic care death due lack qualiti care rather lack access mani proven qualiti improv qi intervent exist high incom countri implement lowmiddl incom countri lmic face challeng current theori driven systemat articul knowledg factor support success scale qi periop care set lack aim identifi periop safeti qi intervent appli scale lmic evalu implement mechan use implement theori

D058996;D006296

T058;T057

36,288,813

compar risk thrombosi thrombocytopenia syndrom thromboembol event associ differ covid vaccin intern network cohort studi five european countri us quantifi compar risk thrombosi thrombocytopenia syndrom thromboembol event associ use adenovirus base covid vaccin versus mrna base covid vaccin

D000086663;D013921;D013923;D013927

T200;T047;T046

36,288,809

food insecur diet qualiti suboptim diabet manag among us adult diabet healthi diet recommend support diabet manag includ hbac blood pressur cholesterol abc control food insecur barrier consum healthi diet determin preval food insecur diet qualiti among us adult diabet associ abc manag

D005523;D003920

T081;T047

36,288,808

impact packag health nutrit psychosoci support wash intervent deliv preconcept pregnanc earli childhood period birth outcom linear growth month age factori individu randomis control trial determin effect integr concurr deliveri health nutrit water sanit hygien wash psychosoci care intervent preconcept period alon pregnanc earli childhood throughout preconcept pregnanc earli childhood birth outcom linear growth month age compar routin care

D012499;D000067250

T061;T090;T058

36,288,806

patient safeti cultur associ factor secondari health care capit region denmark influenc specialti healthcar profess gender aim explor influenc healthcar profession hcps specialti profess gender length employ percept six dimens patient safeti cultur psc relat characterist two dimens safeti climat percept manag

D061214;D017751

T058;T080;T057

36,288,802

genom signatur mitonuclear coevolut mammal mitochondri mt nuclear encod protein integr aerob respir requir co function among gene product fundament differ genom differ evolutionari rate inherit mechan select pressur set stage incompat interact product two genom mitonuclear coevolut hypothesi posit incompat may avoid evolut one genom select complementari chang interact gene encod genom nuclear compens deleteri mtdna chang offset compensatori nuclear chang often invok primari mechan mitonuclear coevolut yet direct evid support nuclear compens rare use data mammalian speci repres eight order show strong correl evolutionari rate mt nuclear encod mt target n mt protein mt non mt target nuclear protein provid strong support mitonuclear coevolut across mammal n mt gene direct mt interact also show strongest correl although n mt gene elev dnds ratio compar mt gene predict nuclear compens n mt site close contact mt protein overrepres sign posit select compar noncontact n mt site contrari predict nuclear compens furthermor tempor pattern n mt mt amino acid substitut support predict nuclear compens even posit select function import residu direct mitonuclear contact overal result strong support mitonuclear coevolut across million year mammalian evolut fail support nuclear compens major mode mitonuclear coevolut

D004272;D050259

T045;T123;T028;T114

36,288,796

enhanc numeraci skill follow team base learn unit state pharmaci student longitudin cohort studi literatur suggest abil numer fulli understood without account social context mathemat activ repres team base learn tbl andragog approach theoret link sociocultur communiti practic learn studi aim quantit explor impact tbl instruct numeraci develop cohort pharmaci student identifi impact tbl instruct numeraci develop social perspect healthcar educ

D013339

T097

36,288,789

particip physic educ class relat physic activ sedentari behavior systemat review aim systemat review summar result assess methodolog qualiti studi analyz relat physic educ particip physic activ sedentari behavior schoolchildren

D057185;D015444

T033;T056;T079;T061

36,288,761

human papillomavirus ee contribut immun escap progress cervic cancer regul mir ppd l axi persist infect human papillomavirus hpv immun escap main caus cervic cancer ee encod hpv may close relat carcinogenesi hpv infect may upregul pd l express result immun escap cervic cancerigenesi evid indic mirna may mediat regul ee pd l therefor aim screen mirna verifi express function bioinformat approach use screen mirna mediat regul ee pd l express mirna pd l hpv hpv cervic cancer cell compar effect ee evalu effect mirna pd l assess gain loss function test final vivo experi conduct verifi effect mirna tumor growth surviv tumor bear mice six mirna screen mir p identifi mir p downregul pd l upregul hpv cell transfect e e ee rescu test show upregul mir p attenu effect ee pd l revers relationship pd l mir p confirm vivo experi suggest mir p upregul inhibit growth transplant tumor target pd l mir p act tumor suppressor cervic cancer hpv ee may promot immun escap cervic cancer cell regul mir ppd l axi use mir p tumor immunotherapi new strategi propos

D002583;D009856;D030361;D035683

T123;T116;T191;T114;T047

36,288,748

real time user feedback support clinic decis support system improv improv clinic decis support cds allow user provid real time feedback interact cds tool creat process respond act feedback

D020000

T058;T170

36,288,737

expositori discours product school age children across two scaffold task school age children encount expositori discours daili classroom skill understand product expositori languag critic academ success purpos studi compar children product two type expositori discours generat retel employ scaffold note take procedur assist children develop sampl twenti six typic develop children year age particip studi expositori generat task children gave explan favorit activ retel task view video provid explan inform video overal expositori generat sampl longer richer content expositori retel sampl demonstr greater lexic divers addit generat sampl contain fewer grammat error retel sampl trend measur syntact complex posit relat across task signific differ sampl type find suggest use scaffold procedur support expositori product result sampl long enough valid analysi children languag product utter averag longer report similar studi without scaffold potenti impact comprehens retel task perform discuss

D007804;D007802

T171;T041

36,288,736

build research initi develop group effort bridg patient partner aphasia research research initi research often littl input group affect result research aim project describ practic embrac patient partner ie individu aphasia spousesfamili member research six webinar develop research patient partner requir prior particip joint confer focus collabor research team confer design base appreci inquiri approach includ patient partner research prioriti plan accomplish across various health domain unit state first organ nation effort unit state support inclus peopl aphasia famili activ partner research process consequ hope futur aphasia research also includ patient partner team research process ecolog valid outcom

D001037

T047;T048

36,288,733

cross section analysi treatment pup germani first data gephard studi group initi treatment patient haemophilia remain challeng choic therapi time dose frequenc still intens debat new treatment option like novel factor concentr non factor therapi broaden discuss

D006467;D002836

T047

36,288,732

platelet sera donor convalesc plasma mild covid show procoagul phenotyp coronavirus diseas covid associ increas thromboembol complic long term alter coagul system acut covid infect still subject research furthermor effect sera convalesc subject platelet known studi investig platelet phenotyp coagul fibrinolysi covid convalesc plasma ccp donor analyz convalesc sera induc effect platelet investig ccp donor histori mild covid infect donor covid use control analyz phosphatidylserin ps extern cdp express glycoprotein vi gpvi shed platelet rich plasma prp incub wash healthi platelet donor sera use flow cytometri coagul fibrinolysi system assess thromboelastometri forti seven ccp donor male femal mean age sd year histori mild covid infect includ median durat acut covid infect day rang find increas ps extern cdp express gpvi shed platelet ccp donor sera ccp donor induc ps extern gpvi shed healthi platelet sera induc cdp express slight albeit statist signific lower ccp donor plasma donor without histori covid one patient show increas maximum clot firm prolong lysi time thromboelastometri find suggest procoagul platelet phenotyp present mild covid furthermor ccp sera affect activ status platelet

D000086382

T047;T067

36,288,729

founder event caus domin childhood epilepsi surviv year weak select pressur genet epilepsi febril seizur plus gef autosom domin famili epilepsi syndrom character distinct phenotyp heterogen within famili scnb cc g pcystrp variant identifi independ multi generat famili gef although variant present popul databas low frequenc strong clinic genet function evid support pathogen recurr variant may due founder event variant inherit common ancestor report evid singl founder event give rise scnb cc g variant independ famili epilepsi common haplotyp observ famili age recent common ancestor estim approxim year ago analysi uk biobank whole exom sequenc data identifi individu variant individu carri haplotyp match epilepsi affect famili suggest instanc variant deriv singl mutat event unusu find variant caus autosom domin earli onset diseas outbr popul persist mani generat attribut relat mild phenotyp carrier incomplet penetr founder event well establish autosom recess late onset disord rare observ earli onset autosom domin diseas find suggest variant present popul low frequenc consid potenti pathogen mild phenotyp incomplet penetr may import contributor genet landscap previous thought

D003294;D004827

T033;T047

36,288,726

neurobiolog long covid persist neurolog neuropsychiatr symptom affect substanti fraction peopl covid repres major compon post acut covid syndrom also known long covid review understood pathobiolog post acut covid impact cns discuss possibl neurobiolog underpin cognit symptom affect covid survivor propos chief mechan may contribut emerg neurolog health crisi

D000086382;D009422;D001523

T047;T067;T048

36,288,725

sar cov infect neuron induc neuroinflamm non human primat model covid sever acut respiratori syndrom coronavirus sar cov etiolog agent coronavirus diseas covid induc plethora neurolog complic patient howev still debat whether sar cov direct infect brain whether cns sequela result system inflammatori respons trigger peripheri use high resolut microscopi investig whether sar cov reach brain viral neurotrop modul age non human primat model covid seven day infect sar cov detect olfactori cortex interconnect region accompani robust neuroinflamm neuron damag exacerb age diabet anim studi provid initi framework identifi molecular cellular mechan under sar cov neurolog complic essenti reduc short long term burden covid

D000086382;D009422

T047;T067

36,288,724

tumor associ macrophag express transcript factor irf promot cell exhaust cancer tumor popul antigen present cell apc includ macrophag subset distinct origin function examin cancer impact mononuclear phagocyt apc murin model breast cancer tumor induc expans monocyt deriv tumor associ macrophag tam activ type dendrit cell dcs express requir transcript factor interferon regulatori factor irf although dcs mediat cytotox lymphocyt ctl prime tumor drain lymph node tam promot ctl exhaust tumor irf requir tam abil present cancer cell antigen tam specif irf delet prevent exhaust cancer cell reactiv ctls suppress tumor growth tumor patient immun infiltr renal cell carcinoma abund tam express irf enrich irf gene express signatur furthermor tam irf signatur co segreg ctl exhaust signatur across multipl cancer type thus ctl exhaust promot tam via irf

D002292;D007680

T191

36,288,719

mettl regul methyl ptch gli sonic hedgehog signal promot tumor progress shh medulloblastoma shh subgroup medulloblastoma shh mb one common malign pediatr tumor aris cerebellum previous show rna methyl particip regul cerebellar develop investig whether dysregul methyl contribut tumorigenesi shh mb show high express methyltransferas mettl associ wors surviv patient shh mb larg number hypermethyl transcript identifi shh mb tumor cell seq find mettl promot tumor progress via activ sonic hedgehog signal mechanist mettl methyl ptch gli rnas regul rna stabil translat import target mettl deplet mettl express treatment catalyt inhibitor stm restrain tumor progress collect studi show critic function mettl methyl shh mb indic potenti role mettl therapeut target shh mb

D002528;D008527

T191

36,288,718

critic development window elavhu depend mrna signatur onset neuron differenti cell type specif gene regulatori program essenti cell differenti function anim neuron high conserv elavhu famili protein promot altern splice polyadenyl mrna precursor creat uniqu neuron transcript isoform assess transcriptom profil neurogenesi success drosophila model engin express differ level elav activ cours develop show elav mediat establish subset neuron mrna isoform onset neuron differenti constitut development bottleneck overcom later nuclear activ paralog found neuron fne loss elav function outsid critic time window result neurolog defect find fne activ earli enough restor elav depend neuron mrna isoform fulli rescu develop find demonstr essenti role robust cellular strategi maintain elav activ intact neuron signatur neurogenesi neuron function

D029721

T123;T116

36,288,717

modif confer thermal vulner hpv e oncotranscript via revers regul reader protein igfbp upon heat stress human papillomavirus hpv induc carcinogenesi critic depend viral earli protein e make e attract therapeut target report e messeng rna mrna contain oncotranscript complex select target heat treatment hpv infect cell viral e mrna modifi n methyladenosin stabil igfbp cellular reader heat treatment downregul e mrna protein destabil igfbp without involv canon heat shock protein revers hpv associ carcinogenesi vitro vivo mechanist heat treatment promot igfbp aggreg presenc modifi e mrna form distinct heat induc e mrna igfbp granul resolv ubiquitin proteasom system collect result show mutual regul rna reader also provid heat treatment base therapeut strategi hpv associ malign specif downregul e mrna igfbp oncogen complex

D052685;D030361

T005;T047

36,288,716

isoform specif inhibit fgfr signal achiev de novo design mini protein cellular signal fibroblast growth factor receptor fgfrs high regul process mediat specif interact distinct subset fibroblast growth factor fgf ligand two fgfr isoform generat altern splice epitheli b mesenchym c isoform investig properti mini protein mb develop silico design strategi bind ligand bind region fgfr describ structur biophys cellular analys demonstr mb bind high affin c isoform fgfr result inhibit cellular signal induc subset fgfs preferenti activ c isoform fgfr notabl mb block interact fgfr klotho protein function antagonist metabol hormon fgf fgf provid mechanist insight strategi develop therapeut diseas driven aberr activ fgfrs

D017468;D005346

T123;T116;T192

36,288,715

target rtnnogo receptor reduc level al protein ataxin gene base therapeut strategi lower ataxin level emerg neurodegen diseas amyotroph later sclerosi al spinocerebellar ataxia type sca addit strategi lower level ataxin could benefici perform genom wide array small interf rna sirna screen human cell identifi rtnr gene encod rtnnogo receptor potent modifi ataxin level rtnr knockdown treatment peptid inhibitor suffici lower ataxin protein level mous human neuron vitro rtnr knockout mice reduc ataxin level vivo provid evid ataxin share role rtnnogo receptor limit axon regener reduct either protein increas axon regrowth follow axotomi data defin rtnnogo receptor novel therapeut target al sca implic target ataxin potenti treatment follow nerv injuri

D000690;D020754

T047

36,288,714

genom wide crispr screen reveal v atpas drug target lower level al protein ataxin mutat ataxin gene atxn caus neurodegen disord amyotroph later sclerosi al spinocerebellar ataxia type sca therapeut strategi use antisens oligonucleotid target atxn enter clinic trial human addit way decreas ataxin level could lead cheaper less invas therapi elucid ataxin normal regul perform genom wide fluoresc activ cell sort fac base crispr cas screen human cell identifi gene encod compon lysosom vacuolar atpas v atpas modifi endogen ataxin protein level multipl fda approv small molecul v atpas inhibitor lower ataxin protein level mous human neuron oral administr least one drug etidron suffici decreas ataxin brain mice togeth propos v atpas drug target al sca demonstr valu fac base screen identifi genet potenti druggabl modifi human diseas protein

D000690;D025262;D020754

T047;T126;T116

36,288,713

elev pentos phosphat pathway flux support appendag regener fundament step regener rapid growth replac lost tissu cell must generat suffici lipid nucleotid protein fuel rapid cell divis defin metabol pathway under regen growth undertak multimod investig metabol reprogram xenopus tropicali appendag regener regener tissu increas glucos uptak howev inhibit glycolysi decreas regener instead glucos funnel pentos phosphat pathway ppp essenti full tail regener liquid chromatographi mass spectrometri lc ms metabolit profil reveal increas nucleotid nicotinamid intermedi requir cell divis use singl cell rna sequenc scrna seq find high prolif cell increas transcript ppp enzym glycolyt enzym ppp inhibit result decreas cell divis specif regener tissu result inform model wherein regener tissu direct glucos toward ppp yield nucleotid precursor drive regen cell prolifer

D010427;D006019

T044

36,288,712

locus coeruleus mediat behavior flexibl behavior flexibl abil adjust behavior strategi respons chang environment conting major hypothesi field posit activ neuron locus coeruleus lc play import role mediat behavior flexibl test hypothesi develop tactil base rule shift detect task mice respond left right whisker deflect context depend manner exhibit vari degre switch behavior record spike activ optogenet tag neuron lc millisecond precis task perform reveal promin grade correl baselin lc activ behavior flexibl higher baselin activ follow rule chang associ faster behavior switch new rule increas baselin lc activ optogenet activ acceler task switch improv task perform overal studi provid import evid reveal link lc activ behavior flexibl

D008125;D062308

T063;T023

36,288,711

express mosquito mirna entomopathogen fungus induc pathogen mediat host rna interfer increas fungal efficaci grow threat insecticid resist prompt urgent need develop addit tool mosquito control entomopathogen fungi provid eco friend altern chemic insecticid one limit use mycoinsecticid relat low virul report approach suppress mosquito immun increas fungal virul engin beauveria bassiana express aed immunosuppress microrna mirna induc host rna interfer rnai immun respons show engin strain produc deliv mirna host cell activ cross kingdom rnai infect suppress mosquito immun target multipl host gene therebi dramat increas fungal virul aed aegypti galleria mellonella larva import express host mirna also signific increas fungal virul insecticid resist mosquito creat potenti insecticid resist manag pathogen mediat rnai pmrnai base approach provid innov strategi enhanc efficaci fungal insecticid elimin likelihood resist develop

D007306;D035683;D000330;D052982

T123;T131;T004;T204;T114

36,288,710

later septum modul cortic state tune respons threat stimuli sudden unexpect environment chang captur attent perceiv potenti danger evok defens behavior state perturb later septum ls produc extrem hyperdefens even innocu stimuli structur influenc stimulus evok defens respons threat percept remain unclear show crhr express neuron mous ls exhibit phasic activ upon detect threaten reward stimuli threat stimulus driven activ predict probabl vigor type defens behavior evok although necessari suffici potenti stimulus trigger defens respons ls crhr neuron promot specif behavior rather stimul elicit negat valenc physiolog arous moreov ls crhr activ track brain state fluctuat drive cortic activ rapid awaken absenc threat togeth find suggest ls direct bottom modul cortic function evok preparatori defens intern state select enhanc respons threat relat stimuli

D005239;D009474

T025;T041

36,288,709

cholinerg control striatal gabaerg microcircuit cholinerg interneuron cin essenti element striatal circuit function although acetylcholin signal via muscarin receptor machr well studi recent data indic postsynapt nicotin receptor nachr locat striatal gabaerg interneuron gin equal critic one exampl cin stimul induc larg disynapt inhibit striatal project neuron spns mediat nachr activ gin although circuit ideal posit modul striatal output neuron involv definit identifi incomplet map cin gin interconnect show cin modul four gin popul via intric mechan involv co activ presynapt postsynapt machr nachr use optogenet demonstr particip tyrosin hydroxylas express gin disynapt inhibit spns via heterotyp electr coupl neurogliaform interneuron altogeth result highlight import cin regul gin microcircuit via complex synapticheterosynapt mechan

D000109;D011978

T123;T121;T116;T192;T109

36,288,708

mtor larp depend regul top mrna poli tail ribosom load translat termin oligopyrimidin top mrnas encod protein synthesi machineri strict regul amino acid sens mtor pathway howev regulatori mechan remain elus demonstr top mrna translat posit correl poli tail length mtor activeamino acid rich condit suggest top mrnas post transcript control poli tail length regul consist tail length top mrnas dynam fluctuat respons amino acid avail poli tail shorten mtor activeamino acid rich condit wherea long tail top mrnas accumul mtor inactiveamino acid starv aa condit rna bind protein larp indispens process larp interact non canon poli polymeras induc post transcript polyadenyl target find illustr larp contribut select accumul top mrnas long poli tail aa result acceler ribosom load onto top mrnas resumpt translat aa

D012261;D001324

T129;T123;T116